The U.S. Food and Drug Administration has given fingolimod a Breakthrough Therapy designation as a treatment for children 10 years and older and adolescents with relapsing multiple sclerosis. ... Read more
Gilenya decreased relapses in children and adolescents with multiple sclerosis in the phase 3 PARADIGMS trial, according to the therapy’s developer, Novartis.
The Swiss company will present ... Read more
A Canadian study showed that child-onset multiple sclerosis (MS) is characterized by increased functional connectivity within the brain, most likely a compensatory effect to preserve function and ... Read more
Nutra Pharma, a US-based biotechnology a company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, ... Read more
Pin It on Pinterest